Let's Pave The Way For An Infection-Free Future with JSQ Lifesciences

Exceptional Medical Solutions

At JSQ Lifesciences, we are committed to revolutionizing infection control through innovation and rigorous research. Our mission is to combat Hospital Acquired Infections (HAIs) and antibiotic-resistant superbugs, ensuring a safer and healthier environment.

About JSQ Lifesciences

Leading the Fight Against Infections

JSQ Lifesciences is an Indian company set up as a joint venture between JVS Products a British R&D company and Athos Trading.  The company has been set up firstly to bring SQ53 a high performance, novel, patented antiseptic to market.

Our company has pioneered advanced antiseptic products to tackle the pressing challenges of Hospital Acquired Infections (HAIs) and antibiotic-resistant superbugs. Committed to the highest quality results, we aim to create a safer and healthier future for all.

Combining scientific rigor with a commitment to safety, these products deliver superior results. Discover how these innovations contribute to a safer, healthier world.

More Info

Innovation to Protect and Promote Global Health.

JSQ Lifesciences India Private Ltd is run by a team of highly qualified professionals, focused on delivering high performance, certified, Indian mademedical products to market. Combining scientific rigor with a commitment to safety, our infection control products deliver superior results. Discover how these innovations contribute to a safer, healthier world.

Dorbimex

a novel high performance antiseptic designed to tackle the pressing challenges of Hospital Acquired Infections (HAIs) and antibiotic-resistant superbugs.

Know More

Zyntidex

advanced disinfectant wipes for non-invasive catheter and medical device care.

Know More

Our Patented Product SQ53

Prevents Infections, Saves Lifes.

Our patented product, SQ53, is the result of extensive research and a deeply personal mission to prevent infections. With proven efficacy against the toughest microbes, it represents a major advance in the fight against antibiotic resistance and infection and can be used to prevent infections before they occur, providing invaluable protection for those at high risk.

More Info

Highlights of JSQ Lifesciences

JSQ’s Competitive Edge

JSQ Lifesciences sets a new standard with its multi-faceted approach to infection prevention, providing a solution that’s low in cytotoxicity, low potential for resistance and a wide spectrum of antimicrobial activity.

More Info
  • Exceptional Residual Activity

Upto 24 hours protection

  • Antimicrobial Efficacy

Effectively combating a wide range of harmful microbes.

  • Enhanced Safety

Ensuring the highest standards of safety are met.

  • Strict Quality Practices

Maintaining the highest quality protocols.

  • Economical Choice

Affordable solutions for infection prevention.

Our Values

Providing the best results

Excellence

SQ53 is formulated to outperform recommended antiseptics.

Collaboration

we work with renowned medical establishments such as Southampton University/UK.

Transparency

SQ53 has been rigorously tested to international standards

Equity

we believe excellent healthcare should be available to everyone

Upto 99.99999% Effective Against Super Bugs.

Upto 99.99999% Effective Against Super Bugs.

You Might Know

Interesting Facts

Starting in October 2016, a team at Apollo Hospitals, India carried out a study using SQ53 (with patients included on compassionate grounds). One of the Apollo doctors had come across SQ53 while working in Oxford and thought it might help to address the high rate of CLABSI (central line- associated bloodstream infection) – a significant cause of morbidity and mortality in hospitalized patients in Indian hospitals. The study used SQ53, as an adjunct to standard insertion and cleaning regimens for intermediate and long-term catheters The use of SQ53 led to a significant drop of CLABSI per 365 catheter days from a mean of 48 to 3, making the use of external lines a real possibility in the healthcare sector in the country.
Starting in October 2016, a team at Apollo Hospitals, India carried out a study using SQ53 (with patients included on compassionate grounds). One of the Apollo doctors had come across SQ53 while working in Oxford and thought it might help to address the high rate of CLABSI (central line- associated bloodstream infection) – a significant cause of morbidity and mortality in hospitalized patients in Indian hospitals. The study used SQ53, as an adjunct to standard insertion and cleaning regimens for intermediate and long-term catheters The use of SQ53 led to a significant drop of CLABSI per 365 catheter days from a mean of 48 to 3, making the use of external lines a real possibility in the healthcare sector in the country.
India’s high bioburden along with it being the home of successful SQ53 trials, makes it the natural place for SQ53 to succeed. Thus, in 2023, JSQ Lifesciences Private India was set up to bring SQ53 to market. Initially time was spent gaining regulatory approval and antiseptic approval was gained at the beginning of 2024.
India’s high bioburden along with it being the home of successful SQ53 trials, makes it the natural place for SQ53 to succeed. Thus, in 2023, JSQ Lifesciences Private India was set up to bring SQ53 to market. Initially time was spent gaining regulatory approval and antiseptic approval was gained at the beginning of 2024.
A further study in 2021 concluded that patients who used SQ53 wipes for more than 90% of the time using specific instructions had 74% decreased CRBSI (catheter related bloodstream infection) rates compared to their previous experience.
A further study in 2021 concluded that patients who used SQ53 wipes for more than 90% of the time using specific instructions had 74% decreased CRBSI (catheter related bloodstream infection) rates compared to their previous experience.

Show no apparent development of anti-microbial resistance (AMR) after sustained use and the ability to eliminate viable but nonculturable bacteria (VBNC) – More Info

Show no apparent development of anti-microbial resistance (AMR) after sustained use and the ability to eliminate viable but nonculturable bacteria (VBNC) – More info

SQ53 consistently outperforms current recommended antiseptics/disinfectants when tested under ‘dirty’ conditions in respect of: residual duration of activity, efficacy, speed of action, safety and biofilm control

SQ53 consistently outperforms current recommended antiseptics/disinfectants when tested under ‘dirty’ conditions in respect of: residual duration of activity, efficacy, speed of action, safety and biofilm control

If you have any questions or need assistance, please reach out to us.

Contact Us

Copyright © 2025 JSQLifesciences. All Rights Reserved.